• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry.

作者信息

Marselis Daan, Hordijk Lucien

机构信息

The Investigative Desk, Amsterdam, Netherlands.

出版信息

BMJ. 2020 Jul 28;370:m2983. doi: 10.1136/bmj.m2983.

DOI:10.1136/bmj.m2983
PMID:32727745
Abstract
摘要

相似文献

1
From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry.从重磅炸弹药物到“小众炸弹药物”：一项有缺陷的立法如何助力制药行业创造新的盈利模式。
BMJ. 2020 Jul 28;370:m2983. doi: 10.1136/bmj.m2983.
2
Generic Competition for Drugs Treating Rare Diseases.治疗罕见病药物的仿制药竞争
J Law Med Ethics. 2020 Dec;48(4):789-795. doi: 10.1177/1073110520979391.
3
Orphan drug pricing may warrant a competition law investigation.孤儿药定价可能需要进行竞争法调查。
BMJ. 2010 Nov 16;341:c6471. doi: 10.1136/bmj.c6471.
4
Does orphan drug legislation really answer the needs of patients?孤儿药立法真的能满足患者的需求吗？
Lancet. 2008 Jun 14;371(9629):2041-4. doi: 10.1016/S0140-6736(08)60873-9.
5
EU to review rare disease drugs market exclusivity.欧盟将审查罕见病药物的市场独占权。
Nat Biotechnol. 2004 Sep;22(9):1061. doi: 10.1038/nbt0904-1061.
6
[Orphan drugs--medications for patients with rare diseases].[孤儿药——用于罕见病患者的药物]
Ugeskr Laeger. 2006 Jun 5;168(23):2236-8.
7
Outrageous prices of orphan drugs: a call for collaboration.孤儿药价格离谱：呼吁合作。
Lancet. 2018 Sep 1;392(10149):791-794. doi: 10.1016/S0140-6736(18)31069-9. Epub 2018 Jul 20.
8
[Orphan drugs: availability, reliability and reimbursement].[罕见病药物：可及性、可靠性与报销]
Ned Tijdschr Geneeskd. 2012;156(17):A4252.
9
Open letter to prime minister David Cameron and health secretary Andrew Lansley.致首相戴维·卡梅伦和卫生大臣安德鲁·兰斯利的公开信。
BMJ. 2010 Nov 16;341:c6466. doi: 10.1136/bmj.c6466.
10
Promoting the development of drugs against rare diseases: what more should be done?推动罕见病药物研发：还有哪些工作需要进一步开展？
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):541-3. doi: 10.1586/erp.12.56.

引用本文的文献

1
Results of health technology assessments of orphan drugs in Germany-lack of added benefit, evidence gaps, and persisting unmet medical needs.德国罕见病药物的卫生技术评估结果——缺乏额外益处、证据空白以及持续存在的未满足医疗需求
Int J Technol Assess Health Care. 2024 Dec 3;40(1):e68. doi: 10.1017/S026646232400062X.
2
New cancer medicines in Europe 2010-2020: comparison of medicines with or without extensions of indications.2010-2020 年欧洲的新型癌症药物：有或无适应症扩展的药物比较。
BMJ Open. 2024 Oct 21;14(10):e083549. doi: 10.1136/bmjopen-2023-083549.
3
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
1995 年至 2020 年间欧洲药品管理局批准的肿瘤药物的附加获益和收益：回顾性队列研究。
BMJ. 2024 Feb 28;384:e077391. doi: 10.1136/bmj-2023-077391.
4
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.孤儿药的成本：威尔士支出的纵向分析。
Orphanet J Rare Dis. 2023 Nov 1;18(1):342. doi: 10.1186/s13023-023-02956-3.
5
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.四个西欧国家在市场独占期满前后的孤儿药价格：目录价格和购买价格的跨国比较。
Appl Health Econ Health Policy. 2023 Nov;21(6):905-914. doi: 10.1007/s40258-023-00832-6. Epub 2023 Sep 26.
6
Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study.南非药学专业本科最后一年学生对药物经济学在实践中应用的认知与准备情况：一项全国性横断面研究
Pharmacy (Basel). 2023 Mar 14;11(2):54. doi: 10.3390/pharmacy11020054.
7
Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to COVID-19 vaccines.自愿还是法律义务？对实现更公平获取 COVID-19 疫苗的两种工具的伦理分析。
Front Public Health. 2023 Jan 26;11:995683. doi: 10.3389/fpubh.2023.995683. eCollection 2023.
8
Industry influence in healthcare harms patients: myth or maxim?医疗保健行业的影响对患者有害：是谬论还是真理？
Breathe (Sheff). 2022 Jun;18(2):220010. doi: 10.1183/20734735.0010-2022. Epub 2022 Jul 12.
9
Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.从美国孤儿药法案的考虑修改和美国及欧盟讨论的价格调控机制调整角度，比较孤儿药在美国和欧盟的价格。
Int J Environ Res Public Health. 2022 Sep 24;19(19):12098. doi: 10.3390/ijerph191912098.
10
Making Sure That Orphan Incentives Tip the Right Way in Europe.确保欧洲孤儿药激励措施发挥正确作用。
Healthcare (Basel). 2022 Aug 23;10(9):1600. doi: 10.3390/healthcare10091600.